However, the development of most PPARα/γ dual agonists (e.g., muraglitazar, tesaglitazar, and aleglitazar) has been abandoned due to serious safety concerns [11], and that of a PPARα/δ dual agonist elafibranor for NASH has been discontinued due to it having no significant benefits [18]. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatohepatitis.